Skip to main content
Clinical Trials/NCT06113432
NCT06113432
Completed
Not Applicable

CPAP Therapy Through a Helmet or a Full Face Mask in Patients With Acute Hypoxemic Respiratory Failure: a Comparative, Cross-over, Physiological Study

I.M. Sechenov First Moscow State Medical University1 site in 1 country30 target enrollmentSeptember 19, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pneumonia, Bacterial
Sponsor
I.M. Sechenov First Moscow State Medical University
Enrollment
30
Locations
1
Primary Endpoint
Inspiratory delta transpulmonary pressure (stress)
Status
Completed
Last Updated
last year

Overview

Brief Summary

Observational and randomized trials have demonstrated the high effectiveness of non-invasive helmet ventilatory support, demonstrating a reduction in intubation rate mortality compared with high-flow and standard oxygen therapy. Some pilot physiological studies have shown physiological benefits of helmets compared to the oronasal mask for non-invasive ventilation. The purpose of the study is to compare markers of patient self-inflicted lung injury (P-SILI), patient's comfort, work of breathing, gas exchange, and hemodynamics in patients with acute hypoxemic respiratory failure (AHRF) during non-invasive ventilation (NIV) in continuous positive pressure (CPAP) mode during an oronasal mask ventilation or a combination of a helmet with high-flow oxygenation as an air flow generator.

Detailed Description

In December 2019, an outbreak of a novel coronavirus emerged in Wuhan, China and rapidly spread worldwide. The World Health Organization (WHO) declared the outbreak a pandemic on March 11th, 2020. The clinical disease (COVID-19) results in critical illness in about 5% of patients with predominant acute respiratory failure. Observational and randomized trials have demonstrated the high effectiveness of non-invasive helmet ventilatory support, demonstrating a reduction in intubation rate mortality compared with high-flow and standard oxygen therapy. Some pilot physiological studies have shown physiological benefits of helmets compared to the oronasal mask for non-invasive ventilation. The purpose of the study is to compare markers of patient self-inflicted lung injury (P-SILI) (measuring esophageal pressure, transpulmonary pressure during inspiration and expiration), the patient's work of breathing (assessment of accessory muscles work) patient's comfort by visual-analog scale, gas exchange (by PaO2/FiO2 and Respiration Oxygenation Index (ROX-index), and hemodynamics in patients with acute hypoxemic respiratory failure (AHRF) during non-invasive pulmonary ventilation (NIV) in continuous positive pressure (CPAP) mode during an oronasal mask ventilation or a combination of a helmet with high-flow oxygenation as an air flow generator.

Registry
clinicaltrials.gov
Start Date
September 19, 2023
End Date
May 30, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients with acute hypoxemic respiratory failure due to community-acquired pneumonia or COVID-19
  • The ratio of the partial pressure of oxygen in arterial blood to the inspiratory fraction of oxygen (PaO2/FiO2) is less than 250 mm Hg while breathing atmospheric air
  • Respiratory rate more than \> 25 per minute.
  • Written informed consent

Exclusion Criteria

  • Patients who achieve the following target parameters with only low-flow oxygen therapy (flow up to 15 l/min): SpO2 \> 93%, the patient does not have a subjective feeling of fatigue, there is no visible work of the auxiliary respiratory muscles of the neck,
  • Unstable hemodynamics (systolic blood pressure \<90 mm Hg or mean arterial pressure \<65 mm Hg) and/or lactic acidosis (lactate \>5 mmol/l and/or clinically diagnosed shock) and/or life-threatening arrhythmia,
  • Metabolic acidosis (pH \<7.30);
  • Patients who were in the ICU for less than 24 hours for any reason
  • Primary or secondary lung diseases (exacerbation of chronic obstructive pulmonary disease (COPD), bronchial asthma, interstitial lung diseases, metastatic lung disease)
  • Cardiogenic pulmonary edema,
  • Chronic diseases in the stag e of decompensation with the development of extrapulmonary organ dysfunction (liver cirrhosis, progression of cancer, CHF),
  • Glasgow Coma Scale score \<14 points,
  • Swallowing disorders
  • Hypercapnia (PaCO2\>45 mmHg),

Outcomes

Primary Outcomes

Inspiratory delta transpulmonary pressure (stress)

Time Frame: 40 minutes

Inspiratory delta transpulmonary pressure

Inspiratory effort

Time Frame: 40 minutes

Delta esophageal pressure

Expiratory delta transpulmonary pressure

Time Frame: 40 minutes

Expiratory delta transpulmonary pressure

Secondary Outcomes

  • Respiratory rate(40 minutes)
  • ROX index(40 minutes)
  • Discomfort visual analog scale (VAS)(40 minutes)
  • Patrick's score(40 minutes)
  • Oxygenation(40 minutes)
  • Noninvasive blood pressure(40 minutes)
  • Heart rate(40 minutes)

Study Sites (1)

Loading locations...

Similar Trials